Innovent Biologics’ Picankibart Shows 64.6% Skin Clearance in Phase II Psoriasis Study
China-based Innovent Biologics, Inc. (HKG: 1801) has announced encouraging results from the multi-center, open Phase...
Livzon Pharmaceutical’s Leuprorelin Acetate Microspheres Passes China’s GQCE
China’s Livzon Pharmaceutical Group Inc., (HKG: 1513, SHE: 000513) has announced that its leuprorelin acetate...
Xi’an Xintong Pharma’s Pradefavir Wins NMPA Nod for Chronic Hepatitis B Treatment
The National Medical Products Administration (NMPA) has granted market approval for pradefavir, a Category 1...
Eli Lilly’s Mounjaro Approved in Hong Kong for Obesity and Type 2 Diabetes Treatment
Eli Lilly & Co. (NYSE: LLY) has received market approval from Hong Kong’s Department of...
Clover Biopharmaceuticals Reports Strong Phase I Results for RSV Vaccine SCB-1019
China-based Clover Biopharmaceuticals Ltd. (HKG: 2197) has announced encouraging additional immunogenicity and safety data from...
Merck and Moderna Launch Phase III Study for Individualized Neoantigen Therapy in Lung Cancer
US pharmaceutical companies Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) and Moderna Inc. (NASDAQ:...
Merck’s Keytruda Gains Two Additional EU Indications for Gynecologic Cancer Treatment
Merck, Sharp & Dohme Inc., known as MSD (NYSE: MRK), has received two additional indication...
WuXi AppTec Reports Q3 2024 Revenues of RMB 10.46 Billion Amid Biosecure Act Challenges
WuXi AppTec Co., Ltd (SHA: 603259), the China-based Contract Development and Manufacturing Organization (CDMO) facing...
Monte Rosa Therapeutics Strikes Licensing Deal with Novartis for VAV1 Degraders
US-based Monte Rosa Therapeutics (NASDAQ: GLUE) has entered into a licensing agreement with Swiss pharmaceutical...
Jiangsu Hengrui Pharmaceuticals Advances Clinical Trials for Cancer Therapies with NMPA Clearance
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received clinical clearance from China’s National Medical...
AstraZeneca’s Fasenra Approved by EU for Eosinophilic Granulomatosis Treatment
UK pharmaceutical giant AstraZeneca Inc. (NASDAQ: AZN) has received marketing approval from the European Commission...
AbbVie Inks $1.4 Billion Deal to Acquire Alzheimer’s Drug Developer Aliada Therapeutics
US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a definitive agreement to acquire all...
CSPC Pharmaceutical’s SYS6020 Receives NMPA Approval for Myasthenia Gravis Clinical Trial
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...
Eli Lilly’s Ebglyss Shows Positive Results in Phase III Study for Atopic Dermatitis Patients Previously Treated with Dupilumab
Eli Lilly & Co. (NYSE: LLY), a leading U.S. pharmaceutical company, has announced the results...
CANbridge Pharmaceuticals Scales Back US Operations, Focuses on China for R&D and Commercialization
CANbridge Pharmaceuticals Inc., (HKG: 1228), a China-based pharmaceutical company specializing in rare diseases, has announced...
Biogen’s Felzartamab Demonstrates Promising Results in Phase II Study for IgA Nephropathy
Biogen Inc. (NASDAQ: BIIB), a prominent biopharmaceutical company based in the U.S., has announced comprehensive...
Humanwell Healthcare Receives NMPA Approval for Chemically Synthesized Semaglutide Clinical Trial
Humanwell Healthcare (Group) Co., Ltd (SHA: 600079), a leading healthcare company based in China, has...
RiboX Therapeutics’ Circular RNA Therapy RXRG001 Gets FDA Green Light for Dry Mouth Clinical Trial
RiboX Therapeutics, a Shanghai-based developer of circular RNA (circRNA) therapies, has announced that it has...
AstraZeneca’s Zoladex Receives NMPA Approval for Higher Dosage Form in Breast Cancer Treatment
AstraZeneca Inc., (AZ, NASDAQ: AZN), a UK-based pharmaceutical giant, has announced that it has received...
MicuRx Pharmaceuticals’ Antibiotic MRX-5 Completes Successful Phase I Clinical Trial in Australia
MicuRx Pharmaceuticals Inc. (SHA: 688373), a Sino-US pharmaceutical company, has announced the successful completion of...